XRF Scientific Limited Logo

XRF Scientific Limited

XRF.AX

(3.2)
Stock Price

1,72 AUD

17.21% ROA

16.91% ROE

26.42x PER

Market Cap.

238.678.300,00 AUD

6.16% DER

2.29% Yield

14.85% NPM

XRF Scientific Limited Stock Analysis

XRF Scientific Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

XRF Scientific Limited Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 DER

The stock has a low debt to equity ratio (8%), which means it has a small amount of debt compared to the ownership it holds

3 Dividend Growth

The company's dividend growth has consistently increased every year in the last five years, indicating a strong track record of positive returns for investors.

4 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

5 ROE

The stock's ROE falls within an average range (14.73%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

6 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

7 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

8 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

9 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (9) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

10 PBV

The stock's elevated P/BV ratio (3.33x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

11 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

XRF Scientific Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

XRF Scientific Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

XRF Scientific Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

XRF Scientific Limited Revenue
Year Revenue Growth
2007 12.587.740
2008 14.706.204 14.41%
2009 16.905.909 13.01%
2010 12.675.259 -33.38%
2011 20.489.230 38.14%
2012 25.886.294 20.85%
2013 23.200.870 -11.57%
2014 21.850.062 -6.18%
2015 20.670.839 -5.7%
2016 21.132.846 2.19%
2017 21.540.489 1.89%
2018 24.250.362 11.17%
2019 29.028.642 16.46%
2020 29.081.431 0.18%
2020 29.081.431 0%
2021 31.292.627 7.07%
2022 40.006.809 21.78%
2023 55.174.587 27.49%
2024 125.524.068 56.04%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

XRF Scientific Limited Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 169.058 100%
2014 78.103 -116.46%
2015 73.836 -5.78%
2016 150.327 50.88%
2017 180.356 16.65%
2018 188.977 4.56%
2019 180.016 -4.98%
2020 0 0%
2020 179.389 100%
2021 150.691 -19.04%
2022 111.789 -34.8%
2023 94.096 -18.8%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

XRF Scientific Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 3.906.138
2008 3.804.458 -2.67%
2009 4.134.289 7.98%
2010 2.321.386 -78.1%
2011 2.302.276 -0.83%
2012 3.471.865 33.69%
2013 3.589.902 3.29%
2014 3.760.155 4.53%
2015 4.003.642 6.08%
2016 4.895.343 18.22%
2017 5.983.732 18.19%
2018 6.423.795 6.85%
2019 6.572.832 2.27%
2020 7.406.446 11.26%
2020 6.727.036 -10.1%
2021 6.748.917 0.32%
2022 7.762.930 13.06%
2023 9.168.504 15.33%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

XRF Scientific Limited EBITDA
Year EBITDA Growth
2007 926.099
2008 1.859.845 50.21%
2009 2.591.261 28.23%
2010 1.150.443 -125.24%
2011 4.746.176 75.76%
2012 5.840.165 18.73%
2013 5.754.031 -1.5%
2014 4.257.322 -35.16%
2015 4.150.902 -2.56%
2016 2.942.111 -41.09%
2017 1.857.985 -58.35%
2018 2.429.823 23.53%
2019 4.008.670 39.39%
2020 4.612.396 13.09%
2020 6.082.970 24.18%
2021 7.610.990 20.08%
2022 9.964.550 23.62%
2023 13.964.770 28.65%
2024 34.238.480 59.21%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

XRF Scientific Limited Gross Profit
Year Gross Profit Growth
2007 5.072.531
2008 5.546.687 8.55%
2009 6.677.347 16.93%
2010 4.808.659 -38.86%
2011 8.512.678 43.51%
2012 9.991.792 14.8%
2013 9.820.233 -1.75%
2014 8.607.383 -14.09%
2015 8.697.982 1.04%
2016 8.581.003 -1.36%
2017 8.880.198 3.37%
2018 9.654.912 8.02%
2019 11.355.629 14.98%
2020 12.244.342 7.26%
2020 11.343.604 -7.94%
2021 12.890.638 12%
2022 16.462.748 21.7%
2023 22.002.439 25.18%
2024 55.828.504 60.59%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

XRF Scientific Limited Net Profit
Year Net Profit Growth
2007 108.385
2008 920.607 88.23%
2009 1.950.592 52.8%
2010 302.879 -544.02%
2011 2.634.983 88.51%
2012 3.579.393 26.38%
2013 3.812.772 6.12%
2014 2.441.258 -56.18%
2015 2.639.463 7.51%
2016 1.537.264 -71.7%
2017 793.851 -93.65%
2018 1.024.007 22.48%
2019 2.137.590 52.1%
2020 3.121.380 31.52%
2020 3.121.380 0%
2021 5.130.455 39.16%
2022 6.083.736 15.67%
2023 7.685.827 20.84%
2024 17.618.164 56.38%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

XRF Scientific Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

XRF Scientific Limited Free Cashflow
Year Free Cashflow Growth
2007 -535.928
2008 -269.828 -98.62%
2009 1.892.181 114.26%
2010 -202.948 1032.35%
2011 1.825.440 111.12%
2012 2.852.277 36%
2013 2.837.955 -0.5%
2014 2.204.129 -28.76%
2015 3.827.394 42.41%
2016 -2.695.075 242.01%
2017 -1.685.392 -59.91%
2018 -893.942 -88.53%
2019 3.355.197 126.64%
2020 3.448.287 2.7%
2021 3.858.764 10.64%
2022 2.634.400 -46.48%
2023 7.634.086 65.49%
2024 5.412.110 -41.06%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

XRF Scientific Limited Operating Cashflow
Year Operating Cashflow Growth
2007 50.881
2008 354.199 85.63%
2009 3.023.077 88.28%
2010 773.757 -290.7%
2011 2.594.256 70.17%
2012 3.662.256 29.16%
2013 4.130.765 11.34%
2014 2.612.495 -58.12%
2015 4.123.719 36.65%
2016 425.064 -870.14%
2017 156.181 -172.16%
2018 807.783 80.67%
2019 3.876.306 79.16%
2020 4.201.693 7.74%
2021 4.511.387 6.86%
2022 3.153.897 -43.04%
2023 8.416.518 62.53%
2024 5.920.307 -42.16%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

XRF Scientific Limited Capital Expenditure
Year Capital Expenditure Growth
2007 586.809
2008 624.027 5.96%
2009 1.130.896 44.82%
2010 976.705 -15.79%
2011 768.816 -27.04%
2012 809.979 5.08%
2013 1.292.810 37.35%
2014 408.366 -216.58%
2015 296.325 -37.81%
2016 3.120.139 90.5%
2017 1.841.573 -69.43%
2018 1.701.725 -8.22%
2019 521.109 -226.56%
2020 753.406 30.83%
2021 652.623 -15.44%
2022 519.497 -25.63%
2023 782.432 33.6%
2024 508.197 -53.96%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

XRF Scientific Limited Equity
Year Equity Growth
2007 12.195.420
2008 13.604.028 10.35%
2009 15.126.359 10.06%
2010 14.742.151 -2.61%
2011 19.405.172 24.03%
2012 26.516.852 26.82%
2013 29.060.448 8.75%
2014 29.118.380 0.2%
2015 29.765.291 2.17%
2016 30.406.972 2.11%
2017 30.763.097 1.16%
2018 31.724.490 3.03%
2019 33.811.367 6.17%
2020 35.635.471 5.12%
2021 39.102.913 8.87%
2022 43.348.029 9.79%
2023 49.577.667 12.57%
2024 55.540.208 10.74%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

XRF Scientific Limited Assets
Year Assets Growth
2007 15.047.102
2008 15.654.936 3.88%
2009 16.953.784 7.66%
2010 16.812.896 -0.84%
2011 24.187.459 30.49%
2012 30.605.208 20.97%
2013 31.257.436 2.09%
2014 31.495.504 0.76%
2015 31.827.979 1.04%
2016 33.697.177 5.55%
2017 34.711.230 2.92%
2018 37.930.055 8.49%
2019 41.719.191 9.08%
2020 45.167.590 7.63%
2021 48.373.180 6.63%
2022 55.558.439 12.93%
2023 65.547.618 15.24%
2024 68.233.120 3.94%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

XRF Scientific Limited Liabilities
Year Liabilities Growth
2007 2.851.682
2008 2.050.908 -39.04%
2009 1.827.425 -12.23%
2010 2.070.745 11.75%
2011 4.782.287 56.7%
2012 4.088.356 -16.97%
2013 2.196.988 -86.09%
2014 2.377.124 7.58%
2015 2.062.688 -15.24%
2016 3.290.205 37.31%
2017 3.948.133 16.66%
2018 6.205.565 36.38%
2019 7.907.824 21.53%
2020 9.532.119 17.04%
2021 9.270.267 -2.82%
2022 12.210.410 24.08%
2023 15.969.951 23.54%
2024 12.692.912 -25.82%

XRF Scientific Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.43
Net Income per Share
0.06
Price to Earning Ratio
26.42x
Price To Sales Ratio
3.99x
POCF Ratio
29.02
PFCF Ratio
37.02
Price to Book Ratio
4.28
EV to Sales
3.84
EV Over EBITDA
14.35
EV to Operating CashFlow
28.43
EV to FreeCashFlow
35.68
Earnings Yield
0.04
FreeCashFlow Yield
0.03
Market Cap
0,24 Bil.
Enterprise Value
0,23 Bil.
Graham Number
0.76
Graham NetNet
0.11

Income Statement Metrics

Net Income per Share
0.06
Income Quality
0.91
ROE
0.17
Return On Assets
0.13
Return On Capital Employed
0.25
Net Income per EBT
0.66
EBT Per Ebit
0.93
Ebit per Revenue
0.24
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0.08
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.44
Operating Profit Margin
0.24
Pretax Profit Margin
0.23
Net Profit Margin
0.15

Dividends

Dividend Yield
0.02
Dividend Yield %
2.29
Payout Ratio
0.41
Dividend Per Share
0.04

Operating Metrics

Operating Cashflow per Share
0.06
Free CashFlow per Share
0.05
Capex to Operating CashFlow
0.2
Capex to Revenue
0.03
Capex to Depreciation
1.04
Return on Invested Capital
0.17
Return on Tangible Assets
0.17
Days Sales Outstanding
58.1
Days Payables Outstanding
44.35
Days of Inventory on Hand
184.17
Receivables Turnover
6.28
Payables Turnover
8.23
Inventory Turnover
1.98
Capex per Share
0.01

Balance Sheet

Cash per Share
0,09
Book Value per Share
0,40
Tangible Book Value per Share
0.28
Shareholders Equity per Share
0.4
Interest Debt per Share
0.03
Debt to Equity
0.06
Debt to Assets
0.05
Net Debt to EBITDA
-0.54
Current Ratio
3.75
Tangible Asset Value
0,04 Bil.
Net Current Asset Value
0,03 Bil.
Invested Capital
56199060
Working Capital
0,03 Bil.
Intangibles to Total Assets
0.24
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
17343150
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

XRF Scientific Limited Dividends
Year Dividends Growth
2008 0
2009 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

XRF Scientific Limited Profile

About XRF Scientific Limited

XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries in Australia, Canada, and Europe. It operates through Capital Equipment, Precious Metals, and Consumables segments. The Capital Equipment segment designs, manufactures, and services automated fusion equipment, and high temperature test and production furnaces, as well as general laboratory equipment. The Precious Metals segment manufactures products for the laboratory and platinum alloy markets. The Consumables segment manufactures chemicals and other supplies for analytical laboratories. The company was founded in 1972 and is based in Osborne Park, Australia.

CEO
Mr. Vance Stazzonelli
Employee
0
Address
86 Guthrie Street
Osborne Park, 6017

XRF Scientific Limited Executives & BODs

XRF Scientific Limited Executives & BODs
# Name Age
1 Mr. Vance Stazzonelli
MD, Company Secretary & Director
70
2 Mr. Andrew Watson B.Comm, CA
Chief Financial Officer & Joint Company Secretary
70
3 Mr. Stephen Prossor
Business Development Manager
70

XRF Scientific Limited Competitors